



THE
BLADDER CANCER
COMPANY

Photocure ASA - Share option grant to members of the board of directors

Oslo, Norway, 7 August 2026 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to the members of the board of directors.

The Company has issued the annual share options to the members of the board of directors in accordance with the resolution made under section 5 of the annual general meeting held 26 June 2026. Chairperson, Dylan Huss Hallerberg, was issued 19,221 share options, and the other members of the board, Neal Shore and Ghizlane Tagmouti were issued 10,377 options each. The strike price was set at a 10% premium to the weighted average closing price in the 30 business days following the annual general meeting on 26 June 2026, which corresponds to a strike price of NOK 58.90 per share.

Primary insider notifications pursuant to the Market Abuse Regulation Article 19 are attached.

For further information, please contact:

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news

This information is subject to the disclosure requirements pursuant to Article 19 of the Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act.